Regenesis Secures FDA Clearance for Latest Reprieve by Regenesis™ Device

Wednesday, August 23, 2023

Regenesis Biomedical, a company dedicated to advancing medical devices for safe and drug-free pain management, has announced a significant achievement - the launch of the all-new Reprieve by Regenesis™ device (Reprieve). In a notable distinction, Reprieve emerges as the singular shortwave diathermy device designed for home use, drawing from Regenesis' foundational technology of pulsed electromagnetic energy.

Aligned with our overarching vision of promoting enduring well-being, marked by vitality and active living, we are delighted to declare the receipt of official clearance from the Food and Drug Administration (FDA) for the innovative Reprieve by Regenesis device. This regulatory endorsement empowers us to introduce our therapeutic solution across a wide array of pain indications, particularly within the Department of Veterans Health Administration (VA) domain. This strategic expansion targets a market segment that surpasses our current scope by a significant 16-fold margin.An exceptional facet of this latest device is its unique dual-treatment applicator option, underscoring our commitment to diverse and enhanced pain management approaches.



Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO Summit - USAHealthcare CMO Summit - USAHealthcare CFO, Financial Strategy & Revenue Cycle SummitHealthcare CEO & Executive Strategy Summit